Grifols Class A/GRF

€8.48

-2.23%
-
1D1W1MYTD1YMAX

About Grifols Class A

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Ticker

GRF

Sector

Healthcare

Trading on

BME

Industry

Biotechnology & Drugs

CEO

Thomas Glanzmann

Employees

23,744

Headquarters

Barcelona, Spain

Grifols Class A Metrics

BasicAdvanced
€5.25B
Market cap
95.13
P/E ratio
€0.09
EPS
0.51
Beta
-
Dividend rate
€5.25B
0.51261
€15.92
€6.36
4.33M
2.786
1.292
158.216
173.625
51.488
1.56%
0.84%
0.99%
1.06%
95.129
0.797
0.999
7.27%
-55.02%

What the Analysts think about Grifols Class A

Analyst Ratings

Majority rating from 18 analysts.
Buy

Price Targets

Average projection from 16 analysts.
109.2% upside
High €27.80
Low €7.00
€8.48
Current price
€17.74
Average price target

Grifols Class A Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
3.15% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€1.77B
10.77%
Net income
€55.9M
-6.05%
Profit margin
3.15%
-15.32%

Grifols Class A Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 58.54%
QuarterlyAnnual
Q4 22
Q2 23
Q4 23
Actual
€0.05
€0.17
-
Expected
€0.28
€0.41
€0.53
Surprise
-82.14%
-58.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Grifols Class A stock?

Grifols Class A (GRF) has a market cap of €5.25B as of April 14, 2024.

What is the P/E ratio for Grifols Class A stock?

The price to earnings (P/E) ratio for Grifols Class A (GRF) stock is 95.13 as of April 14, 2024.

Does Grifols Class A stock pay dividends?

No, Grifols Class A (GRF) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Grifols Class A dividend payment date?

Grifols Class A (GRF) stock does not pay dividends to its shareholders.

What is the beta indicator for Grifols Class A?

Grifols Class A (GRF) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Grifols Class A stock price target?

The target price for Grifols Class A (GRF) stock is €17.74, which is 109.2% above the current price of €8.48. This is an average based on projections from 16 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Grifols Class A stock

Buy or sell Grifols Class A stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing